Y-Intercept (HK)’s 9 Meters Biopharma NMTR Stock Holding History

Y-Intercept (HK)’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,216	Closed	-$48K	–	1364
2022 Q2	$48K	Buy	+9,216	New	+$86.8K	0.01%	754

Other funds holding NMTR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

ODFS

O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Y-Intercept (HK)'s NMTR Position: Q3 2022 in Review

Y-Intercept (HK) sold out of 9 Meters Biopharma (NMTR) in Q3 2022, closing a stake of 9,216 shares — an estimated $48K sold.

Y-Intercept (HK) first reported a position in NMTR in Q2 2022 and held it in 1 quarter. The position peaked at $48K in Q2 2022. 74 funds tracked by Wall St. Rank hold NMTR as of Q3 2022.

Y-Intercept (HK) reported no remaining 9 Meters Biopharma position as of Q3 2022 after selling out during the quarter.
Y-Intercept (HK) sold 9,216 9 Meters Biopharma shares in Q3 2022, an estimated $48K.
Y-Intercept (HK) first reported a position in 9 Meters Biopharma in Q2 2022 and held it in 1 quarter.
Y-Intercept (HK)'s 9 Meters Biopharma position peaked at $48K in Q2 2022.
74 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.